Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Molecular Partners AG    MOLN   CH0256379097

MOLECULAR PARTNERS AG (MOLN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
10/09/2018 10/10/2018 10/11/2018 10/12/2018 10/15/2018 Date
20.05(c) 19.34(c) 18.4(c) 18.14(c) 18.44 Last
46 844 40 484 47 203 15 267 34 624 Volume
-4.52% -3.54% -4.86% -1.41% +1.65% Change
More quotes
Financials (CHF)
Sales 2018 15,7 M
EBIT 2018 -40,4 M
Net income 2018 -41,2 M
Finance 2018 86,0 M
Yield 2018 -
Sales 2019 24,5 M
EBIT 2019 -38,6 M
Net income 2019 -39,5 M
Finance 2019 27,6 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 19,0x
EV / Sales2019 14,6x
Capitalization 385 M
More Financials
Company
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders.It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to... 
More about the company
Surperformance© ratings of Molecular Partners AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MOLECULAR PARTNERS AG
08/30MOLECULAR PARTNERS REPORTS KEY FINAN : Promising MP0250 clinical data in oncolog..
TE
07/21MOLECULAR PARTNERS : Allergan, Molecular Partners AMD drug non-inferior to Lucen..
AQ
07/20ALLERGAN : AGN), Molecular Partners Announce Two Positive Phase 3 Clinical Trial..
AQ
07/20MOLECULAR PARTNERS : In two PhIII wins for Allergan/Molecular Partners, wet AMD ..
AQ
07/20ALLERGAN : announce clinical trial success for abicipar
AQ
07/20ALLERGAN : abicipar pegol non-inferior to Lucentis, but increases inflammation
AQ
07/19Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials..
TE
06/21Molecular Partners Appoints Pamela A. Trail as Chief Scientific Officer; Mich..
TE
06/15Molecular Partners presents updated results from its ongoing Phase 2 combinat..
TE
05/16Molecular Partners to present final MP0250 Phase 1 data at ASCO Annual Meetin..
TE
More news
Sector news : Bio Therapeutic Drugs
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
09/28FDA Approves Libtayo to Treat Advanced Cutaneous Squamous Cell Carcinoma
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
08/30Molecular Partners $MOLN Reports Key Financials for H1 18 and Corporate Highl..
1
08/14Molecular Partners $MOLN Enrollment resumed on MP0274 phase I in HER2-positiv.. 
07/22Allergan’s eye contender cannot knock Eylea off its perch: Regeneron’s Eylea .. 
07/20Allergan, Molecular Partners’ AMD drug non-inferior to Lucentis  
07/20Allergan, Molecular Partners eye drug meets main goal in two studies  
More tweets
Qtime:11
News from SeekingAlpha
09/12Molecular Partners (MLLCF) Presents At Morgan Stanley 16th Annual Global Heal.. 
08/31Molecular Partners AG 2018 Q2 - Results - Earnings Call Slides 
07/20Molecular Partners (MLLCF) Abicipar As Validation For The DARPin - Slideshow 
Chart MOLECULAR PARTNERS AG
Duration : Period :
Molecular Partners AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MOLECULAR PARTNERS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 38,8  CHF
Spread / Average Target 114%
EPS Revisions
Managers
NameTitle
Patrick Amstutz Chief Executive Officer & Director
William Matt Burns Chairman
Michael Tobias Stumpp Chief Operating Officer
Andreas Emmenegger Chief Financial Officer
Andreas Harstrick Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MOLECULAR PARTNERS AG-31.03%388
GILEAD SCIENCES2.72%93 985
VERTEX PHARMACEUTICALS20.99%44 892
REGENERON PHARMACEUTICALS2.18%39 451
NEUROCRINE BIOSCIENCES, INC.43.68%9 776
GENMAB-10.38%8 786